MediFormatica’s Post

Today at #EANM24, we are presenting additional positive preclinical data supporting our DLL3-targeting #RadioDARPin Therapeutic (RDT) candidate MP0712, which is in co-development with Orano Med for patients with small cell lung cancer. Some highlights include: 🔹 Dose-dependent efficacy observed with favorable safety profile 🔹 Attractive tumor to kidney ratios shown in biodistribution studies 🔹 Picomolar affinity and high specificity for DLL3 seen strongly support anticipated precision of alpha radiation delivery 🔹 Molecular Partners and Orano Med are preparing for clinical entry in 2025 Stop by our oral presentation between 8-9:30 AM CET and learn more here: https://lnkd.in/eZm5F7Qn #radiopharmaceutical #oncology #cancerresearch

Marc-Henry PITTY, MD, CEO of Oregon Therapeutics, "To date, our first-in-class #metabolicinhibitor, XCE853, has exhibited robust preclinical efficacy in both in vitro and in vivo models across multiple #cancer types. Lantern’s (NASDAQ: LTRN) #RADR®AI platform will leverage the in vitro and in vivo data to potentially advance XCE853 development in a highly targeted manner and will help inform disease indications and #biomarker signatures that can aid in the design of future #clinicaltrials and in the pursuit of combination therapies with other approved cancer drugs. Our team is looking forward to efficiently selecting among the landscape of ideal development options and efficiently de-risking future clinical development decisions." https://lnkd.in/gabi_27S #biotech #france #texas #oncology #artificialIntelligence

Marc-Henry PITTY, MD, CEO of Oregon Therapeutics, "To date, our first-in-class #metabolicinhibitor, XCE853, has exhibited robust preclinical efficacy in both in vitro and in vivo models across multiple #cancer types. Lantern’s (NASDAQ: LTRN) #RADR®AI platform will leverage the in vitro and in vivo data to potentially advance XCE853 development in a highly targeted manner and will help inform disease indications and #biomarker signatures that can aid in the design of future #clinicaltrials and in the pursuit of combination therapies with other approved cancer drugs. Our team is looking forward to efficiently selecting among the landscape of ideal development options and efficiently de-risking future clinical development decisions." https://lnkd.in/g8XPQSsa #biotech #france #texas #oncology #artificialIntelligence

At the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, independent investigators presented preclinical data demonstrating the therapeutic potential of Cyclacel Pharmaceuticals, Inc. fadraciclib in colorectal cancer models. Fadraciclib significantly inhibited tumor growth, triggered apoptosis, and induced anaphase catastrophe in patient-derived organoids (PDOs) and xenografts (PDX). These findings support fadraciclib's potential as a novel treatment in multiple tumor types by targeting key molecular features of cancer. Learn more: https://bit.ly/3YliEaC #CancerResearch #Biotech #Innovation

Antibody-drug conjugates (ADCs) are transforming personalized oncology by enabling precise drug delivery to cancer cells, thereby optimizing efficacy and minimizing off-target effects. However, existing in vitro preclinical models fall short in capturing the complexity of tumor heterogeneity, which is crucial for accurately assessing ADCs' potential. We understand the difficulties and limitations so we develop Single-AI Chip, to provide unprecedented resolution at single cell response to study antigen heterogeneity and drug resistance at early preclinical stage of ADC candidate development. It’s time to upgrade your preclinical testing pipeline and select the best candidates for clinical trials!! “Make you testing precise with Provectus Therapeutics.”

The newest report from Clarivate is out. Download it now!

🚀 Presenting ADC Digest for April 2024! 🔬 💊Adcentrx Therapeutics to showcase Preclinical findings of Nectin-4 ADC Program at AACR Annual Meeting 2024 💊Datopotamab deruxtecan BLA accepted in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer 💊Ipsen licenses Sutro ADC in $900m deal 💊Caris Life Sciences partners with Merck KGaA to discover cancer targets and fast-track ADC development Stay tuned for more updates and breakthroughs in the world of Antibody-Drug Conjugates! 💪🔬 #ADC #CancerResearch #Innovation #ADCnews #CIScientists #Antibodydrugconjugate

A significant unmet medical need demands novel approaches to understand cancer drug resistance. An integrated approach can be beneficial in early drug discovery. This exciting webinar outlines a four-step preclinical strategy to tackle cancer drug resistance. It will also provide examples of models with resistance to targeted therapy or immuno-therapeutics, describing the key features, challenges, and their applications. Register today! #CancerResearch #DrugResistance #Bioscience

A significant unmet medical need demands novel approaches to understand cancer drug resistance. An integrated approach can be beneficial in early drug discovery. This exciting webinar outlines a four-step preclinical strategy to tackle cancer drug resistance. It will also provide examples of models with resistance to targeted therapy or immuno-therapeutics, describing the key features, challenges, and their applications. Register today! #CancerResearch #DrugResistance #Bioscience

The clinical development of ADCs can be complex. 💡 Antibody-drug conjugates (ADCs) offer a novel approach to targeted #cancer treatment, and are being increasingly used in combination with other agents including as first-line cancer therapies. The FDA has just released comprehensive guidelines for optimising clinical pharmacology studies for ADCs, addressing crucial factors like dosing strategies. 📃 Physiomics plc’s team of dedicated scientists can help companies accelerate the path to success in ADC development. 🚀 Leveraging our expertise in quantitative pharmacology and PK/PD modelling, we offer comprehensive support at every stage, from selecting lead ADC candidates to optimising dosing strategies. Reach out to learn more! #antibodydrugconjugates #drugdevelopment #pharma #biotech #pkpd #qsp #mathematicalmodelling #cancer #oncology #dosing #optimaldose